AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00862225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IG-RD-001 / Ze 339
Description: Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
Study NCT01004484 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acidified dairy snack
Description: A 4 oz. cup of acidified dairy snack, once daily.
Study NCT00304954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Daclizumab
Description: Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
Study NCT04936412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation brace
Description: Rehabilitation brace
Study NCT04936412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation brace
Description: Rehabilitation brace
Study NCT01746628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy with FloSeal
Description: Evaluation of the effects of intrauterine FloSeal
Study NCT01746628 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hysterectomy with FloSeal
Description: Evaluation of the effects of intrauterine FloSeal
Study NCT00304954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infliximab
Description: Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
Study NCT00304954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
Study NCT00304954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Rapamycin
Description: Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
Study NCT04304950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evening Group
Description: Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 pm and 11:00 pm.
Study NCT04304950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morning Group
Description: Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 am and 11:00 am.
Study NCT01999790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blepharotomy
Description: upper eyelid surgery by blepharotomy
Study NCT01999790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior approach
Description: upper eyelid surgery by posterior approach
Study NCT01889862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMN165 20mg/day
Description: BMN165 20mg/day self-administered daily
Study NCT01889862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMN165 40mg/day
Description: BMN165 40mg/day self-administered daily
Study NCT01889862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-drug placebo, self-administered daily
Study NCT04607967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Oxygen
Description: Study participants are suffering from an acute hypoxemic respiratory distress. They have to be treated with oxygen-therapy that could be administered using a conventional oxygen device (study group CO) or High Flow Nasal Oxygen (study group HNFO). During the first 60 minutes following patients admission, patients will be randomized to one of the two study groups. In both groups, the failure of the treatment will be evaluated by the need for a therapeutic escalation fours hours after the treatment initiation.
Study NCT02808455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Treatment A)
Description: Four 100-mg capsules of pacritinib administered as a single oral dose
Study NCT00877266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perineural mepivicaine catheter placed via ultrasound or electrical stimulation
Description: Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.
Study NCT00003070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril maleate
Study NCT00003070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT02808455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Treatment B)
Description: A single 80-mg oral solution dose of pacritinib
Study NCT00251810 — intervention group
Intervention type: DEVICE
Intervention: Cerebral State Monitor
Description: All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
Study NCT00380068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Oral tablets taken once daily.
Study NCT04207190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV
Study NCT03474289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: Monotherapy
Study NCT02787226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine Infiltration
Description: Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.
Study NCT02787226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Perineural Ropivicaine Infusion
Description: Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.
Study NCT05093179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep tissue massage
Description: Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.
Study NCT05093179 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic massage
Description: The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.
Study NCT02173626 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Training
Description: Participants enrolled on a first-come, first-serve basis, engaging in three 90-minute in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls. Video-module trainings were available at all times, to be accessed at the participants' convenience. Journals and a guided meditation audio library were also provided.
Study NCT02924571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate (BMAC) + Allograft
Description: Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest. Harvest BMAC System delivers high stem cell concentration to the graft site.
Study NCT02924571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Bone Morphogenetic Protein-2 (BMP)
Description: INFUSE rhBMP-2 Bone Graft used according to its approved FDA labels, both from an anterior approach using titanium cages as well as from a posterior interbody approach using polyetheretherketone (PEEK) cages.
Study NCT02924571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft
Description: Autograft with bone marrow aspirate.
Study NCT04487145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.
Study NCT04487145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.
Study NCT01335464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching BIBF1120, BID
Study NCT01335464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: BIBF1120 BID (twice daily)
Study NCT01674842 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Once daily, Monday - Friday for six weeks
Study NCT01674842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenously, once weekly for six weeks
Study NCT01615302 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mucosa advancement flap
Description: Mucosa advancement flap will be performed at the starting point of the fistula in the rectum
Study NCT01615302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucosa advancement flap
Description: Mucosa advancement flap will be performed at the starting point of the fistula in the rectum
Study NCT01615302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP)
Description: The PRP will be injected into the fistula, after the mucosa advancement flap was created.~For the PRP we will need to take 55 millilitres of blood of the patient. This blood will be centrifuged into PRP.
Study NCT04897100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Achilles tendon tenotomy
Description: Achilles tendon tenotomy during Ponseti treatment for clubfoot
Study NCT04897100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Achilles tendon tenotomy
Description: Achilles tendon tenotomy during Ponseti treatment for clubfoot
Study NCT02444156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indoor rowing
Study NCT02521454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBRT
Study NCT04207190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04207190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04207190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT04207190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Given PO
Study NCT04243876 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: paraoxanase enzyme level
Description: presence of paraoxonase enzyme deficiency and associated troponin elevation
Study NCT01416792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Centrifugation
Study NCT01416792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple-pass hemofiltration
Description: The residual volume from the CPB circuit is pumped though a hemofilter for multiple passes removing the crystalloid component thereby concentrating the plasma.
Study NCT01458574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10 mg orally (PO) twice a day (BID)
Study NCT01458574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP690,550
Description: CP-690,550 5 mg orally (PO) twice a day (BID)
Study NCT01458574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 10 mg orally (PO) twice a day (BID)
Study NCT02959489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alzheimer's Disease Risk Disclosure
Description: Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
Study NCT02959489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure
Description: Subjects will learn their own elevated or not elevated amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
Study NCT03980470 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TrueFidelity
Description: TrueFidelity (Deep Learning Image Reconstruction, DLIR) software by GE Healthcare.~The medical device in question is a novel reconstruction algorithm for raw CT data which is based on artificial intelligence approaches, namely deep-learning iterative reconstruction (DLIR). This DLIR algorithm will be installed on the console of the CT Revolution scanning device, which is in routine clinical use for cardiac CT scans at the Department of Nuclear Medicine at the University Hospital Zurich. Purpose of this installation is the assessment of the performance of the DLIR algorithm during a limited time span of six weeks.~The algorithm will be CE-marked at the time of installation and use (statement by GE Healthcare provided separately). Its intended use is the reconstruction of CT datasets.~Of note, the novel DLIR algorithm will not substitute any clinical routine procedures currently in use. That is, diagnosis will still be made using the standard reconstruction algorithms.
Study NCT04197947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro Omega
Description: A neurophysiological navigation system NeuroOmegaTM (Alpha Omega. Israel) was implemented in our group and the operation of this system for aDBS experiment is proved to be successful (Fig 9, 10). This system was proved by both FDA and tFDA. The aDBS stimulation algorithm will be integrated with NeuroOmegaTM. The aDBS stimulation control will achieve through self-developed algorithms or built-in scripting of the system. We introduce NeuroOmega system to conduct the designed aDBS experiment for its multifunction and safety. Our group has established collaboration with Department of Eelectronic Engineering in Chang Gung University (Co-PI HL Chan) and BERTEC in National Ciao Tung University (Co-PI MD Ker). Three postdoctor fellows and one senior engineer have been working on the operation of this aDBS system.~All hardware and software problems could be sorted out in time.
Study NCT01196975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccine GSK2282512A
Description: Single intramuscular dose
Study NCT02515357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle
Description: Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean lifestyle (food and food group consumption according to the Mediterranean diet, beneficial culinary practices, seasonality and locality of foods consumed, socialization during meals, adequate rest during the day through night sleep and siesta nap, sleep hygiene recommendations and adoption of a physically active lifestyle) and at achieving a 5-10% weight loss.
Study NCT02515357 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: General written instructions regarding the adoption of a healthy lifestyle.
Study NCT02515357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean dietary pattern (food and food group consumption according to the Mediterranean diet, beneficial culinary practices and seasonality and locality of foods consumed) and at achieving a 5-10% weight loss.
Study NCT02741297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS) System
Description: Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
Study NCT03703999 — intervention group
Intervention type: DEVICE
Intervention: Type 1 diabetic patients freestyle libre
Description: patients selected to use freestyle libre
Study NCT01891006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
Study NCT01196975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluLavalTM-VB
Description: Single intramuscular dose
Study NCT02939638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based diet
Description: Weekly instructions will be given to the participants in the intervention group about following vegan diet.
Study NCT01196975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluLavalTM-YB
Description: Single intramuscular dose
Study NCT00747799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib plus Cisplatin and 5-fluorouracil
Description: Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)~* Sorafenib 400 mg bid per daily . Every 21-day cycles.~* Cisplatin 80 mg/m2 day d1, every 21 days cycle.~* 5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles
Study NCT01365494 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified Chick Embryo Cell Inactivated Rabies Vaccine
Description: Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
Study NCT02960529 — intervention group
Intervention type: PROCEDURE
Intervention: extra-peritoneal high ligation of hernia
Study NCT02960529 — intervention group
Intervention type: PROCEDURE
Intervention: intraabdominal high ligation of hernia
Study NCT01556113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omega diet
Description: Eligible subjects will receive omega rich diet for 12 weeks with weekly appointments to obtain food records, draw serum samples and provide meals.
Study NCT02939638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Description: Participants will be asked to continue their usual diets for the 16-week study period.
Study NCT02506725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prenatal care in groups
Description: We will do prenatal care in groups using centering care pregnancy methodology
Study NCT03252132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-week resistance training
Description: Training will consist of a minimum of 5 supervised training sessions every 2 weeks and each session will be approximately 60 minutes in duration. Patients will be performing resistance training consisting of at least 3 exercises affecting the largest muscle groups of the body, training the most basic movement patterns that work the entire body as a coordinated system. Patients will train according to a linear progressive model with a slow increase in weight every training session focusing on the flexors, extensors of the ankle and knee and on flexors, extensors and abductors of the hip.
Study NCT01803997 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pink and Dude Chef Afterschool Cooking Program
Description: 12 educational cooking classes: two classes per week for six weeks (2 hours each)
Study NCT01605045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-save group
Description: Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
Study NCT01605045 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique
Description: Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
Study NCT01503905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2, iv injection, day1, every 21 days
Study NCT01503905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: 80mg/ m2, iv injection, day1, every 21 days
Study NCT01503905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 500 mg/m2, iv injection, day1, every 21 days
Study NCT01503905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified radical mastectomy or breast-conserving Surgery
Description: Two weeks after four cycles of neoadjuvant chemotherapy
Study NCT01188954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 50 ml/mg
Study NCT01188954 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: Normal Saline/Water